tirzepatide hfpef ESC 2025: study supports use of semaglutide, in cardiometabolic patients Has Tirzepatide Scaled the HFpEF/Obesity
Description
GLP-1s are providing better weight-loss outcomes than the previous AOMs
What dosage of semaglutide is most effective
Rumors about compounded semaglutide bans circulate regularly online, creating confusion among people seeking affordable weight loss therapy
At the 2023 ADA Scientific Sessions in San Diego this week, researchers unveiled full results of the SURMOUNT-2 clinical trial evaluating tirzepatide for weight loss in adults with obesity or overweight and type 2 diabetes
